Mazor Robotics Ltd. (NASDAQ:MZOR) had its target price upped by Barclays PLC from $24.00 to $28.00 in a research report sent to investors on Tuesday morning. The firm currently has an overweight rating on the stock.
Several other brokerages also recently commented on MZOR. Zacks Investment Research upgraded shares of Mazor Robotics from a sell rating to a hold rating and set a $22.00 target price on the stock in a report on Tuesday, July 19th. B. Riley assumed coverage on shares of Mazor Robotics in a research note on Thursday, October 6th. They set a neutral rating and a $25.00 price target for the company. Needham & Company LLC reaffirmed a hold rating on shares of Mazor Robotics in a research note on Tuesday, August 2nd. Finally, Standpoint Research assumed coverage on shares of Mazor Robotics in a research note on Friday, July 8th. They set a buy rating and a $30.00 price target for the company. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $26.25.
Mazor Robotics (NASDAQ:MZOR) opened at 24.48 on Tuesday. Mazor Robotics has a 1-year low of $8.31 and a 1-year high of $26.55. The company’s 50-day moving average is $23.38 and its 200 day moving average is $18.27. The firm’s market capitalization is $530.56 million.
Mazor Robotics (NASDAQ:MZOR) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. The firm had revenue of $8.30 million for the quarter, compared to the consensus estimate of $8.51 million. Mazor Robotics had a negative net margin of 60.75% and a negative return on equity of 42.30%. The business’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the company posted ($0.05) EPS. On average, equities analysts expect that Mazor Robotics will post ($0.71) EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the stock. Iguana Healthcare Management LLC boosted its position in Mazor Robotics by 60.0% in the second quarter. Iguana Healthcare Management LLC now owns 200,000 shares of the company’s stock valued at $3,596,000 after buying an additional 75,000 shares in the last quarter. Menta Capital LLC boosted its position in Mazor Robotics by 25.0% in the second quarter. Menta Capital LLC now owns 46,848 shares of the company’s stock valued at $842,000 after buying an additional 9,366 shares in the last quarter. EAM Investors LLC purchased a new position in Mazor Robotics during the second quarter valued at $2,348,000. Cookson Peirce & Co. Inc. purchased a new position in Mazor Robotics during the second quarter valued at $192,000. Finally, Candriam Luxembourg S.C.A. purchased a new position in Mazor Robotics during the second quarter valued at $1,079,000. 18.71% of the stock is owned by institutional investors and hedge funds.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.